Related Experiment Video
Updated: May 21, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Novel agents in mantle cell lymphoma
Marcus S Noel1, Jonathan W Friedberg, Paul M Barr
1University of Rochester Medical Center, James P. Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA. marcus_noel@urmc.rochester.edu
Best Practice & Research. Clinical Haematology
|June 13, 2012
Summary
Novel agents show promise for treating mantle cell lymphoma (MCL), a rare non-Hodgkin lymphoma with a poor prognosis. Early trials highlight targeted therapies and BH-3 mimetics for improved patient outcomes.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- Mantle cell lymphoma (MCL) is a mature B cell neoplasm comprising 5-7% of non-Hodgkin lymphomas.
- Current therapeutic options for MCL offer a poor overall prognosis, necessitating the development of novel treatments.
Purpose of the Study:
- This review focuses on early-phase clinical trials investigating promising novel agents for mantle cell lymphoma.
- To highlight the potential of targeted signaling pathway inhibition and other emerging therapies in MCL treatment.
Main Methods:
- Review of early-phase clinical trials in mantle cell lymphoma.
- Analysis of targeted agents including inhibitors of spleen tyrosine kinase, phosphoinositide 3-kinase, and Bruton's tyrosine kinase.
- Evaluation of BH-3 mimetics and histone deacetylase inhibitors in MCL.
Main Results:
- Early trials demonstrate promise for novel agents targeting key signaling pathways in MCL.
- Inhibitors of spleen tyrosine kinase, phosphoinositide 3-kinase, and Bruton's tyrosine kinase are under active investigation.
- BH-3 mimetics and histone deacetylase inhibitors also show potential in MCL treatment.
Conclusions:
- Targeting B cell receptor signaling pathways offers a promising therapeutic strategy for mantle cell lymphoma.
- Further understanding of cellular signaling will expand treatment options and improve MCL prognosis.
- Novel agents in early-phase trials hold hope for enhancing the therapeutic armamentarium against MCL.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:16Primary Lymphoid Organs
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
01:18Lymphoid Cells and Tissues
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...